Anthem Biosciences IPO Price Band at Rs 540–570 per Share

Mumbai, 9 July 2025: Anthem Biosciences, a prominent contract research, development, and manufacturing organisation (CRDMO), has announced the price band of its upcoming initial public offering (IPO) at ₹540–570 per equity share. The ₹3,395-crore public offer is expected to open for subscription between July 14 and July 16. Anchor investors may place bids on July 11.

Entire IPO Proceeds to Go to Selling Shareholders, Not the Company

The public issue, amounting to ₹3,395 crore, is entirely structured as an Offer for Sale (OFS) by the promoters, existing investors, and other shareholders. Consequently, Anthem Biosciences will not directly receive any capital inflow from Anthem Biosciences IPO proceeds. At the top end of the price band, the company’s implied valuation exceeds ₹31,800 crore.

Anthem’s Focus on Innovation Strengthens Sector Credibility

Founded in 2006, Anthem Biosciences has consistently built its reputation on high-end innovation and technology-driven manufacturing. The company operates across the pharmaceutical value chain and is known for fermentation-based active pharmaceutical ingredients (APIs). These include probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars—each playing a key role in modern therapeutics.

Expanding Manufacturing Footprint Set to Support Long-Term Growth

Currently, Anthem runs two manufacturing facilities in Karnataka: Unit I in Bommasandra and Unit II in Harohalli. Together, these offer a custom synthesis capacity of 270 kL and a fermentation capacity of 142 kL, as of March 31, 2025. Additional expansion projects are underway—Harohalli is being scaled further, while Unit III, operated by Neoanthem Lifesciences Pvt Ltd, is expected to begin production in the first half of FY26.

Robust Financial Performance Reflects Business Momentum

In FY25, Anthem Biosciences delivered a 30% year-on-year increase in revenue from operations, reaching ₹1,844 crore, compared to ₹1,419 crore in FY24. Profit after tax (PAT) also rose by 23%, touching ₹451 crore. This performance underlines the company’s operational efficiency and market demand resilience.

Allocation Break-Up and Listing Timeline Shared

Anthem has confirmed the following IPO allocation structure:

• 50% of the offer is reserved for Qualified Institutional Buyers (QIBs)
• 35% for Retail Individual Investors (RIIs)
• 15% for Non-Institutional Investors (NIIs)

The company’s shares are expected to be listed on both the BSE and NSE on July 21, marking its debut on public exchanges.

Backing from Global and Domestic Lead Managers

The IPO is being led by a consortium of major investment banks and financial advisors:

• JM Financial Ltd
• Citigroup Global Markets India
• J.P. Morgan India
• Nomura Financial Advisory and Securities (India) Pvt Ltd

These firms bring global placement capabilities and robust investor access to the offer.

Competing With Established Players in the Life Sciences Sector

In the listed space, Anthem Biosciences will join the ranks of sector peers such as:

• Sai Life Sciences Ltd
• Syngene International
• Suven Life Sciences
• Divi’s Laboratories

These companies represent established players in CRAMS (Contract Research and Manufacturing Services) and life sciences segments, positioning Anthem Biosciences in a competitive but opportunity-rich industry landscape

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations